Common Toxicities of CDK4/6 Inhibitors in Patients With HR+/HER2- Metastatic Breast Cancer
The panel explains how treatment experience with CDK4/6 inhibitors varies for patients with HR+/HER- breast cancer, and which agents are best tolerated.
EP: 1.Importance of Multidisciplinary Care for Patients With HR+/HER- Breast Cancer
EP: 2.Barriers to Optimal Care in Patients With HR+/HER- Breast Cancer
EP: 3.Clinical Scenario: A 60-Year-Old Woman With Newly Diagnosed Breast Cancer
EP: 4.Considerations for Chemotherapy Dosing in Patients With HR+/HER- Breast Cancer
EP: 5.Helping Patients With HR+/HER2- Breast Cancer Access Abemaciclib
EP: 6.Updates in Adjuvant Therapy for HR+/HER- Breast Cancer From ASCO 2023: The NATALEE Trial
EP: 7.Monitoring and Treating Lymphedema in Patients With HR+/HER- Breast Cancer
EP: 8.Frontline CDK4/6 Inhibitors in HR+/HER2- Metastatic Breast Cancer
EP: 9.Considerations for Use of CDK4/6 Inhibitors in HR+/HER2- Metastatic Breast Cancer
Now Viewing
EP: 10.Common Toxicities of CDK4/6 Inhibitors in Patients With HR+/HER2- Metastatic Breast Cancer
EP: 11.Utility of Primary Tumor Surgery for De Novo Metastatic Breast Cancer
EP: 12.Unmet Needs in the Treatment of HR+/HER2- Breast Cancer
Related Videos
Related Content
